ConductScience.org, home

Comparison · NCT03296813-a084e1c1

Torsemide vs Furosemide: All-cause Mortality, as Measured by Follow-up Phone Call or NDI

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Torsemide vs Furosemide: All-cause Mortality, as Measured by Follow-up Phone Call or NDI. Trial comparisons, record NCT03296813-a084e1c1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03296813-a084e1c1

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2610.2390.284wilson
Risk in group 20.2620.240.285wilson
Risk difference, group 1 minus group 2-0.00125-0.03340.0309newcombe hybrid score
Risk ratio, group 1 over group 20.9950.881.13log
Odds ratio, group 1 over group 20.9940.8411.17log
Number needed to treat, for one fewer participant with the outcome on Torsemide than on Furosemide801from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1TorsemideOral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~Torsemide: Loop diuretic3731,431OG000
Group 2Furosemide
Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:~1 mg oral torsemide = 2-4 mg oral furosemide~1 mg oral or intravenous bumetanide = 40 mg oral furosemide~Furosemide: Loop diuretic
3741,428OG001

Outcome

Type
PRIMARY
Title
All-cause Mortality, as Measured by Follow-up Phone Call or NDI
Description
Death information was obtained from the Call Center through 30 months for patients 1-500, through 24 months for patients 501-1000, through 18 months for patients 1001-1500, and through 12 months for the remaining patients (except those who were randomized \< 12 months when the study was stopped by the DSMB). Also death information was obtained through searches of the 2018-2021 National Death Index (NDI) database.
Time frame
up to 30 months
Population

Source ClinicalTrials.gov

Trial

Title
TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
NCT number
NCT03296813
Phases
PHASE3
Conditions
Heart Failure
Interventions
Torsemide, Furosemide
Lead sponsor
Duke University
Results first posted
2025-10-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03296813-a084e1c1